Skip to Main Content
Prescriber's Letter
Menu
    • Products
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • Natural Medicines
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber's Letter
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Charts
    • COVID-19 Resources
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • Opioid Resources
    • Transitions of Care Resources
    • Journal Club
  • New Drugs
    • New Drugs
    • First Time Generics
  • Help
    • User Support
    • Contact Us
  • GO TO CE/CME & Training

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

  1. Home
  2. Browse
  3. Psychiatry
  4. ADHD

ADHD

  • ADHD (70)
    • Natural Medicines/Supplements (4)
    • Treatment (57)
  • Anxiety (22)
  • Bipolar Disorder (12)
  • Depression (249)
  • Mental Health (22)
  • Resources (164)
  • Schizophrenia (54)
  • Sleep Disorders (88)
  • Substance Use Disorder (209)
61 - 70 of 70 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
Guideline: AAP Policy Statement on Cardiovascular Monitoring and Stimulant Drugs for ADHD (Addendum May 2008: On May 28, 2008, the American Academy of Pediatrics (AAP) released a statement on cardiovascular monitoring in children and adolescents taking ADHD medications. The AAP does not recommend screening ECGs unless the patient's history, family history, or the physical examination raises concerns.) June 2008
Guideline: Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs (2008) June 2008
Guideline: Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs (Correction) (2009) June 2008
Commentary: Cardiovascular Screening and Monitoring Of Children and Adolescents Receiving ADHD Drugs June 2008
Patient Education: Patient Handout to Go Along with Your MedGuide for ADHD Drugs June 2008
Chart: Drug Treatment for Attention Deficit Hyperactivity Disorder February 2006
Other: Safety Concerns of ADHD Drugs August 2005
Other: Attention-deficit Hyperactivity Disorder in Adults: An Update October 2004
Other: New Product: Concerta (Extended-Release Methylphenidate) September 2000
Other: Natural Medicines for Attention Deficit-Hyperactivity Disorder (ADHD) September 2000
  • « Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • About Us
  • Our Mission
  • Our Team
  • Testimonials
  • Careers
  • Newsroom
  • Products
  • Pharmacist Solutions
  • Prescriber Solutions
  • Hospital Solutions
  • Retail Solutions
  • Group Practice Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.

© Therapeutic Research Center. All Rights Reserved